| h-debate-c017235110f | Glymphatic Enhancement Through Controlled Sleep Depth Modulation | 0.00 | 0.55 | N/A (Sleep Architecture) | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-e9062cec160 | Chronotherapeutic Orexin Modulation for Tau Clearance | 0.00 | 0.55 | HCRTR1/HCRTR2 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-18cf98ca |
| h-debate-44c554c8661 | Compensatory RBP Expression Therapy | 0.00 | 0.55 | ELAVL1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-d311450401b | Mitochondrial RNA Processing Enhancement | 0.00 | 0.55 | LRPPRC | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-c31c367bbbe | RNA Modification Enzyme Modulation | 0.00 | 0.55 | METTL3 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-c6005bc2428 | Cross-Disease RNA Granule Dissolution Therapy | 0.00 | 0.55 | G3BP1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-9531e908c33 | Proteostasis Network Activation for RBPs | 0.00 | 0.55 | HSPA1A | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-0425e09671f | RNA Splicing Corrector Compounds | 0.00 | 0.55 | TARDBP | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-68d9c9c1 |
| h-debate-b1eb50b5e4e | Astrocyte Priming Therapy for Preconditioning Neuroprotection | 0.00 | 0.55 | GFAP | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-166187b528e | Fatty Acid Metabolism Enhancers for Activity-Dependent Neurodegeneration | 0.00 | 0.55 | CPT1A | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-0d42b94d251 | LRP1-ARF1 Lactylation Inhibitors for Metabolic Neuroprotection | 0.00 | 0.55 | ARF1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-d86d79b9d94 | TAK1 Pathway Modulators for Hypothalamic Metabolic Disorders | 0.00 | 0.55 | MAP3K7 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-ccbced20c91 | Mitochondrial Transfer Enhancers for Synaptic Dysfunction | 0.00 | 0.55 | MIRO1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-51c4248ae68 | CD38 Agonist Therapy for Alzheimer's Disease | 0.00 | 0.55 | CD38 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-8c3d8c6d1a9 | Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotection | 0.00 | 0.55 | NDUFS1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-89432b95 |
| h-debate-42a75b89701 | Epigenetic Clock Reversal Through Targeted DNA Demethylation | 0.00 | 0.55 | DNMT1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-d2fa5138b6c | Temporal Epigenetic Clock Synchronization Therapy | 0.00 | 0.55 | CLOCK | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-01c9c9962d7 | Protein Aggregation-Epigenetic Stress Response Modulation | 0.00 | 0.55 | PSMD1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-bfe1b83aa19 | Inflammaging-Epigenome Decoupling Strategy | 0.00 | 0.55 | NFKB1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-d028b27e4d0 | Mitochondrial-Nuclear Epigenetic Communication Restoration | 0.00 | 0.55 | SOD2 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-0b950b4ed02 | Epigenetic Clock Biomarker-Guided Combination Therapy | 0.00 | 0.55 | Multiple (SIRT1, MTOR, NFKB1) | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-334658fce29 | NAD+ Metabolic Rescue Via Autophagy-Epigenetic Coupling | 0.00 | 0.55 | SIRT1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-bc5f270e |
| h-debate-99e31e7ddb3 | Anti-CAA Immunotherapy for Glymphatic Rescue | 0.00 | 0.55 | APP, PSEN1, C1QA | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-b1fcf8fa0bf | Arteriolosclerosis-Targeted Perivascular Space Restoration | 0.00 | 0.55 | ACTA2, COL4A1, MMP9 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-97553319570 | Perivascular Inflammation Resolution Therapy | 0.00 | 0.55 | TREM2, AQP4, C1QA | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-e123259d9f9 | Chronotherapeutic Glymphatic Enhancement | 0.00 | 0.55 | CLOCK, ARNTL, PER2, CRY1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-c6e5ca34453 | Dual Proteinopathy Clearance via Enhanced Drainage | 0.00 | 0.55 | ACTA2, PDGFRB, PROX1 | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-76b52c1666e | Circadian Melatonin Therapy for Glymphatic Enhancement | 0.00 | 0.55 | MTNR1A, MTNR1B, CLOCK, ARNTL | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-1e511c421d9 | Sleep Architecture Optimization via Glymphatic Pacing | 0.00 | 0.55 | GABRA1, ADORA1, ADRA2A | proposed | 2026-04-28 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-debate-f74e7f8e196 | Akkermansia muciniphila Metabolite Inhibition | 0.00 | 0.55 | Akkermansia_Mucinase | proposed | 2026-04-28 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-eb3d3ffc951 | Circadian-Synchronized Microbiome Intervention | 0.00 | 0.55 | CLOCK | proposed | 2026-04-28 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-7199453b125 | Mediterranean Diet Metabolite Synthesis via Engineered Probiotics | 0.00 | 0.55 | Custom_Metabolic_Pathway | proposed | 2026-04-28 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-2c43f3388d9 | Vagal Nerve Stimulation Combined with Probiotic Therapy | 0.00 | 0.55 | CHAT | proposed | 2026-04-28 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-46c5d88e90f | Enteric Nervous System Reprogramming via Microbial Neurotransmitter Modulation | 0.00 | 0.55 | TDC | proposed | 2026-04-28 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-b83436f40ef | Inflammasome-Targeted Microbiome Modulation Therapy | 0.00 | 0.55 | NLRP3 | proposed | 2026-04-28 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-75f5e7789a5 | Prevotellaceae-Derived Butyrate Supplementation as Neuroprotective Therapy | 0.00 | 0.55 | HDAC1/HDAC2 | proposed | 2026-04-28 | sda-2026-04-01-gap-20260401-225149 |
| h-debate-04ae559d2f9 | Metabolic Reprogramming Through TREM2 Modulation | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | SDA-2026-04-06-gap-001 |
| h-debate-3423407b441 | Stage-Dependent TREM2 Modulation Strategy | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | SDA-2026-04-06-gap-001 |
| h-debate-8b90a687b11 | Splicing-Based TREM2 Rescue Therapy | 0.00 | 0.55 | TREM2 | proposed | 2026-04-28 | SDA-2026-04-06-gap-001 |
| h-debate-bad19704d4f | Apolipoprotein E-Mediated Senescent Cell Targeting System | 0.00 | 0.55 | APOE, LRP1, CDKN1A | proposed | 2026-04-28 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| h-debate-7f08c3e04c9 | Circadian-Synchronized Senolytic Delivery | 0.00 | 0.55 | CLOCK, ARNTL, ATG5 | proposed | 2026-04-28 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| h-debate-482db234f55 | Oligodendrocyte Precursor Cell Senescence as Primary Driver of White Matter Dege | 0.00 | 0.55 | BCL2L1, SOX10, PDGFRA | proposed | 2026-04-28 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| h-debate-0cf134d5d9b | Selective Microglial Senescence Targeting via P16INK4A-Guided Senolytics | 0.00 | 0.55 | CDKN2A, BCL2L1, BCL2 | proposed | 2026-04-28 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| h-debate-96d47c1edea | Fisetin-Based Senomorphic Therapy for Preserving Beneficial Senescent Functions | 0.00 | 0.55 | SIRT1, FOXO3, GFAP | proposed | 2026-04-28 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| h-debate-7d54c1a9944 | Temporal SASP Modulation Rather Than Complete Senolytic Clearance | 0.00 | 0.55 | MTOR, RELA, NLRP3 | proposed | 2026-04-28 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| h-debate-62934d147e8 | Senescence-Induced Tau Propagation Blockade | 0.00 | 0.55 | MAPT, CDKN2A, BCL-2 family | proposed | 2026-04-28 | SDA-2026-04-02-gap-senescent-clearance-neuro |
| h-var-7ca5d46fa8 | LAMP2A Upregulation to Enhance Chaperone-Mediated Autophagy for Tau Clearance in | 0.00 | 0.00 | LAMP2A | proposed | 2026-04-28 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-var-e44be8a8cc | Cell-Type-Specific TFEB Modulation Combined with Trehalose for Targeted Alzheime | 0.00 | 0.00 | TFEB | proposed | 2026-04-28 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-var-346a45a59f | LAMP1 Overexpression to Enhance Lysosomal Capacity Independent of TFEB in Aged S | 0.00 | 0.00 | LAMP1 | proposed | 2026-04-28 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-var-dd29f57963 | GLUT1-Mediated Carrier-Conjugate Delivery Strategy | 0.00 | 0.00 | LDLR | proposed | 2026-04-28 | SDA-2026-04-12-gap-debate-20260410-112908-13c403ee |